News & AnalysisLynk Pharmaceuticals picks up $50m Series BLynk Pharmaceuticals, a pharmaceutical R&D company, has secured $50 million in Series B financing.ByIris Dorbian27 August 2021•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsHealthcareBriefs